Alivus Life Sciences Q1 FY27 Net Profit at ₹160.08 Crore, Revenue at ₹662.82 Crore
Alivus Life Sciences reported Q1 FY27 results with total income at ₹662.82 crore and net profit at ₹160.08 crore. Basic EPS stood at ₹13.04. The results were approved by the Board on July 30, 2026.
The financial results are material for investors and stakeholders, impacting the company's valuation and future investment decisions.
The company reported an increase in net profit and revenue compared to the same quarter in the previous year, indicating positive financial performance.
Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) announced its unaudited financial results for the first quarter ended June 30, 2026. The Board of Directors approved these results in a meeting that commenced at 4:45 p.m. and concluded at 5:50 p.m. on July 30, 2026.
For the quarter ended June 30, 2026, the company reported a total income of ₹6,628.15 million (₹662.82 crore), with revenue from operations at ₹6,404.14 million (₹640.41 crore) and other income at ₹224.01 million (₹22.40 crore). Total expenses were ₹4,505.92 million (₹450.59 crore), leading to a profit before tax of ₹2,122.23 million (₹212.22 crore).
The net profit after tax for the period stood at ₹1,600.76 million (₹160.08 crore). Basic earnings per share were ₹13.04, and diluted earnings per share were ₹13.01. The company's paid-up equity share capital increased to ₹245.48 million due to the allotment of 3,100 equity shares under the Employee Stock Option Scheme, 2021.
The financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) and have undergone a limited review by the statutory auditors, Walker Chandiok & Co LLP, who expressed an unmodified review conclusion. The company operates in a single segment: Active Pharmaceutical Ingredient (API).
What to do with a filing like this
Alivus Life Sciences Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Alivus Life Sciences Limited. Read the original for the full detail.